Trial Profile
Research About the Differences Between Chidamide Taken Daily and Twice a Week in Pharmacokinetics
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tucidinostat (Primary)
- Indications T-cell lymphoma
- Focus Therapeutic Use
- 12 Dec 2017 Status changed to active, no longer recruiting as per results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 07 Sep 2016 New trial record